Venous thromboembolism is a significantly underestimated cancer complication, occurring in up to half of cancer patients and detecting in up to 20% of them during the course of their malignant disease. We have developed a multivariable predictive model for thromboembolic events risk assessment in patients with lymphoma. This newly defined Thrombosis Lymphoma (ThroLy) score is more specific for lymphoma patients than any other available score targeting thrombosis risk in cancer patients.
ThroLy score considers some particular characteristics of lymphoma patients, such as extranodal localization and mediastinal involvement. In addition to having a strong positive predictive value, the score is not limited to either hospitalized or outpatient settings, and does not require non-routine laboratory analyses.
An idea to create new more precise model for predicting thromboembolic events in patients with hematological malignancies initiated an adventurous process which resulted in development of ThroLy score, which is certainly a great step to a successful prevention, early detection, and treatment of this type of complications in lymphoma patients. This is also a starting point to further validations and eventual implementation of ThroLy score into clinical guidelines and practice.Dr. Srdjan Nikolovski, MD
Am J Hematol 2016 Oct 22;91(10):1014-9. Epub 2016 Jul 22.
Clinic for Hematology, Lymphoma Center, Clinical Centre Serbia, Belgrade.
Download full-text PDF